These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
275 related articles for article (PubMed ID: 32659428)
21. Molecular and biologic analysis of histone deacetylase inhibitors with diverse specificities. Newbold A; Matthews GM; Bots M; Cluse LA; Clarke CJ; Banks KM; Cullinane C; Bolden JE; Christiansen AJ; Dickins RA; Miccolo C; Chiocca S; Kral AM; Ozerova ND; Miller TA; Methot JL; Richon VM; Secrist JP; Minucci S; Johnstone RW Mol Cancer Ther; 2013 Dec; 12(12):2709-21. PubMed ID: 24092806 [TBL] [Abstract][Full Text] [Related]
22. Odd-chain fatty acids as novel histone deacetylase 6 (HDAC6) inhibitors. Ediriweera MK; To NB; Lim Y; Cho SK Biochimie; 2021 Jul; 186():147-156. PubMed ID: 33965456 [TBL] [Abstract][Full Text] [Related]
23. Targeting HSP90-HDAC6 Regulating Network Implicates Precision Treatment of Breast Cancer. Yu S; Cai X; Wu C; Liu Y; Zhang J; Gong X; Wang X; Wu X; Zhu T; Mo L; Gu J; Yu Z; Chen J; Thiery JP; Chai R; Chen L Int J Biol Sci; 2017; 13(4):505-517. PubMed ID: 28529458 [TBL] [Abstract][Full Text] [Related]
24. Ricolinostat, a selective HDAC6 inhibitor, shows anti-lymphoma cell activity alone and in combination with bendamustine. Cosenza M; Civallero M; Marcheselli L; Sacchi S; Pozzi S Apoptosis; 2017 Jun; 22(6):827-840. PubMed ID: 28315173 [TBL] [Abstract][Full Text] [Related]
25. Combined Ligand and Fragment-based Drug Design of Selective Histone Deacetylase - 6 Inhibitors. Ruzic D; Petkovic M; Agbaba D; Ganesan A; Nikolic K Mol Inform; 2019 May; 38(5):e1800083. PubMed ID: 30632697 [TBL] [Abstract][Full Text] [Related]
26. Isoindoline scaffold-based dual inhibitors of HDAC6 and HSP90 suppressing the growth of lung cancer in vitro and in vivo. Ojha R; Nepali K; Chen CH; Chuang KH; Wu TY; Lin TE; Hsu KC; Chao MW; Lai MJ; Lin MH; Huang HL; Chang CD; Pan SL; Chen MC; Liou JP Eur J Med Chem; 2020 Mar; 190():112086. PubMed ID: 32058238 [TBL] [Abstract][Full Text] [Related]
27. HDAC6 inhibition protects cardiomyocytes against doxorubicin-induced acute damage by improving α-tubulin acetylation. Song R; Yang Y; Lei H; Wang G; Huang Y; Xue W; Wang Y; Yao L; Zhu Y J Mol Cell Cardiol; 2018 Nov; 124():58-69. PubMed ID: 30315806 [TBL] [Abstract][Full Text] [Related]
28. 4-Hydroxybenzoic acid derivatives as HDAC6-specific inhibitors modulating microtubular structure and HSP90α chaperone activity against prostate cancer. Seidel C; Schnekenburger M; Mazumder A; Teiten MH; Kirsch G; Dicato M; Diederich M Biochem Pharmacol; 2016 Jan; 99():31-52. PubMed ID: 26549368 [TBL] [Abstract][Full Text] [Related]
29. Structure, Functions and Selective Inhibitors of HDAC6. Liang T; Fang H Curr Top Med Chem; 2018; 18(28):2429-2447. PubMed ID: 30499393 [TBL] [Abstract][Full Text] [Related]
30. Rutin increases alpha-tubulin acetylation via histone deacetylase 6 inhibition. Çetin Ö; Sari S; Erdem-Yurter H; Bora G Drug Dev Res; 2022 Jun; 83(4):993-1002. PubMed ID: 35266183 [TBL] [Abstract][Full Text] [Related]
31. Dual Targeting Strategies on Histone Deacetylase 6 (HDAC6) and Heat Shock Protein 90 (Hsp90). Bonanni D; Citarella A; Moi D; Pinzi L; Bergamini E; Rastelli G Curr Med Chem; 2022; 29(9):1474-1502. PubMed ID: 34477503 [TBL] [Abstract][Full Text] [Related]
32. A452, an HDAC6-selective inhibitor, synergistically enhances the anticancer activity of chemotherapeutic agents in colorectal cancer cells. Won HR; Ryu HW; Shin DH; Yeon SK; Lee DH; Kwon SH Mol Carcinog; 2018 Oct; 57(10):1383-1395. PubMed ID: 29917295 [TBL] [Abstract][Full Text] [Related]
33. Methods for the expression, purification, and crystallization of histone deacetylase 6-inhibitor complexes. Osko JD; Christianson DW Methods Enzymol; 2019; 626():447-474. PubMed ID: 31606087 [TBL] [Abstract][Full Text] [Related]
34. Posttranslational modification and beyond: interplay between histone deacetylase 6 and heat-shock protein 90. Liu P; Xiao J; Wang Y; Song X; Huang L; Ren Z; Kitazato K; Wang Y Mol Med; 2021 Sep; 27(1):110. PubMed ID: 34530730 [TBL] [Abstract][Full Text] [Related]
35. Identification of novel 1,3-diaryl-1,2,4-triazole-capped histone deacetylase 6 inhibitors with potential anti-gastric cancer activity. Zhang XH; Kang HQ; Tao YY; Li YH; Zhao JR; Ya-Gao ; Ma LY; Liu HM Eur J Med Chem; 2021 Jun; 218():113392. PubMed ID: 33831778 [TBL] [Abstract][Full Text] [Related]
36. Impact of Hybrid-polar Histone Deacetylase Inhibitor m-Carboxycinnamic Acid bis-Hydroxyamide on Human Pancreatic Adenocarcinoma Cells. Kumar D; Sarma P; Bhadra MP; Tangutur AD Anticancer Agents Med Chem; 2019; 19(6):750-759. PubMed ID: 30621566 [TBL] [Abstract][Full Text] [Related]
37. 4-(1-Ethyl-4-anisyl-imidazol-5-yl)-N-hydroxycinnamide - A new pleiotropic HDAC inhibitor targeting cancer cell signalling and cytoskeletal organisation. Mahal K; Kahlen P; Biersack B; Schobert R Exp Cell Res; 2015 Aug; 336(2):263-75. PubMed ID: 26101158 [TBL] [Abstract][Full Text] [Related]
38. Drugging the HDAC6-HSP90 interplay in malignant cells. Krämer OH; Mahboobi S; Sellmer A Trends Pharmacol Sci; 2014 Oct; 35(10):501-9. PubMed ID: 25234862 [TBL] [Abstract][Full Text] [Related]
39. Acetylation/deacetylation and microtubule associated proteins influence flagellar axonemal stability and sperm motility. Chawan V; Yevate S; Gajbhiye R; Kulkarni V; Parte P Biosci Rep; 2020 Dec; 40(12):. PubMed ID: 33200789 [TBL] [Abstract][Full Text] [Related]
40. Development of Multifunctional Histone Deacetylase 6 Degraders with Potent Antimyeloma Activity. Wu H; Yang K; Zhang Z; Leisten ED; Li Z; Xie H; Liu J; Smith KA; Novakova Z; Barinka C; Tang W J Med Chem; 2019 Aug; 62(15):7042-7057. PubMed ID: 31271281 [TBL] [Abstract][Full Text] [Related] [Previous] [Next] [New Search]